BMY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 19.72%. Bristol-Myers Squibb's return on equity of 32.01% beat Gilead Sciences's return on equity of 32.29%.

Bristol-Myers Squibb has a consensus price target of $57.19, signalling upside risk potential of 22.06%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 7.14%. Given that Bristol-Myers Squibb has higher upside potential than Gilead Sciences, analysts believe Bristol-Myers Squibb is more attractive than Gilead Sciences.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Gilead Sciences offers a yield of 2.89% to investors and pays a quarterly dividend of $0.79 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Bristol-Myers Squibb's net income of $2.5B is higher than Gilead Sciences's net income of $1.3B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.55x while Gilead Sciences's PE ratio is 22.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 4.71x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 50.24%. Bristol-Myers Squibb's return on equity of 32.01% beat Johnson & Johnson's return on equity of 30.18%.

Bristol-Myers Squibb has a consensus price target of $57.19, signalling upside risk potential of 22.06%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 10.62%. Given that Bristol-Myers Squibb has higher upside potential than Johnson & Johnson, analysts believe Bristol-Myers Squibb is more attractive than Johnson & Johnson.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Johnson & Johnson offers a yield of 3.24% to investors and pays a quarterly dividend of $1.30 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Bristol-Myers Squibb's net income of $2.5B is lower than Johnson & Johnson's net income of $11B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.55x while Johnson & Johnson's PE ratio is 17.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of 21.68%. Bristol-Myers Squibb's return on equity of 32.01% beat Eli Lilly and's return on equity of 78.25%.

Bristol-Myers Squibb has a consensus price target of $57.19, signalling upside risk potential of 22.06%. On the other hand Eli Lilly and has an analysts' consensus of $955.31 which suggests that it could grow by 33.85%. Given that Eli Lilly and has higher upside potential than Bristol-Myers Squibb, analysts believe Eli Lilly and is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Eli Lilly and offers a yield of 0.79% to investors and pays a quarterly dividend of $1.50 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Bristol-Myers Squibb's net income of $2.5B is lower than Eli Lilly and's net income of $2.8B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.55x while Eli Lilly and's PE ratio is 58.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 13.15x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.93% compared to Bristol-Myers Squibb's net margin of -907.48%. Bristol-Myers Squibb's return on equity of 32.01% beat Moderna's return on equity of -29.23%.

Bristol-Myers Squibb has a consensus price target of $57.19, signalling upside risk potential of 22.06%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 81.63%. Given that Moderna has higher upside potential than Bristol-Myers Squibb, analysts believe Moderna is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.392, which suggesting that the stock is 60.827% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 5.21%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $11.2B, which are larger than Moderna quarterly revenues of $107M. Bristol-Myers Squibb's net income of $2.5B is higher than Moderna's net income of -$971M. Notably, Bristol-Myers Squibb's price-to-earnings ratio is 17.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.00x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.